1877 — Shanghai Junshi Biosciences Share News
0.000.00%
Last trade - 00:00- HK$15.67bn
- HK$18.79bn
- CNY2.50bn
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab
Shanghai Junshi Biosciences HK shares hit 4-week peak on Fosun's licensing deal
Brief: Shanghai Junshi Biosciences To Will Fosun Wanbang Right To Develop, Others, Roconkibart ("Js005") In Greater China Region
Brief: Shanghai Junshi Biosciences Approved Proposal On Change In Shareholding Structure Of Implementing Entity Of Some Sub-Projects
Brief: Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint
Brief: Shanghai Junshi Biosciences Posts Quarterly Net Loss Attributable RMB20.6 Million
Brief: Shanghai Junshi Biosciences Says Shanghai Tanying Plans To Reduce Its Holdings Of Co's Shares
Brief: Shanghai Junshi Biosciences Says From 12 April 2025 To 31 March 2026, Chair Increased Stake
Brief: Shanghai Junshi Biosciences Says As At Mar 16, Controlling Shareholder Increased A Shares By 365,382 Shares For Total RMB12.2 Mln
Brief: Junshi Biosciences' 2025 Net Loss At 875.2 Million Yuan
Brief: Shanghai Junshi Biosciences Says Resolution On Temporary Replenishment Of Liquidity Approved
Brief: Shanghai Junshi Biosciences Says Chairman Intended To Increase Shareholding In Co
Brief: Shanghai Junshi Biosciences Says NMPA Accepts New Drug Applications For Toripalimab-Injection
Brief: Shanghai Junshi Biosciences Prelim 2025 Net Loss 874.4 Million Yuan
Brief: Shanghai Junshi Biosciences Sees 2025 Net Loss At 873 Million Yuan
Brief: Junshi Biosciences' Shareholder To Unload Up To 2% Stake